Review



rat monoclonal anti cd34 antibody  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech rat monoclonal anti cd34 antibody
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2025-02
    94/100 stars

    Images



    Similar Products

    94
    Hycult Biotech rat monoclonal anti cd34 antibody
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech rat anti mouse cd34 antibody
    Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    rat anti mouse cd34 antibody - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech cd34, mouse, mab mec14.7
    Cd34, Mouse, Mab Mec14.7, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34, mouse, mab mec14.7/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    cd34, mouse, mab mec14.7 - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech cd34 antibody
    A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin). B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin). C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H). D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K). E. Macroscopical changes in paratubarian area (microscopical sections in L–N). F. Cavernous hemangioma featuring focal hyalinization. G. The same tumor mass area with higher magnification (haematoxylin-eosin). H. Weak focal hVEGF-A 165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells. I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently <t>CD34</t> <t>positive</t> lining. I. Hematoxylin-eosin. (an arrow points to an area shown in K) J. CD34 immunostaining. K. The same area as in I with higher magnification (stained with Masson Trichrom). Asterix in I and J indicate the same area. L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A 165 immunopositivity shown in N. (hVEGF-A 165 immunostaining). Bar : F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.
    Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34 antibody/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    cd34 antibody - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech mouse monoclonal anti cd34 antibody
    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti <t>CD34</t> antibodies. Angiogenesis was quantified by image analysis of <t>CD34</t> <t>positive</t> stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Mouse Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    mouse monoclonal anti cd34 antibody - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    Image Search Results


    A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin). B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin). C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H). D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K). E. Macroscopical changes in paratubarian area (microscopical sections in L–N). F. Cavernous hemangioma featuring focal hyalinization. G. The same tumor mass area with higher magnification (haematoxylin-eosin). H. Weak focal hVEGF-A 165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells. I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently CD34 positive lining. I. Hematoxylin-eosin. (an arrow points to an area shown in K) J. CD34 immunostaining. K. The same area as in I with higher magnification (stained with Masson Trichrom). Asterix in I and J indicate the same area. L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A 165 immunopositivity shown in N. (hVEGF-A 165 immunostaining). Bar : F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.

    Journal: PLoS ONE

    Article Title: Short and Long-Term Effects of hVEGF-A 165 in Cre-Activated Transgenic Mice

    doi: 10.1371/journal.pone.0000013

    Figure Lengend Snippet: A. Liver: Encapsulated hepatocellular carcinoma was highly necrotic and focally calcified (Haematoxylin-eosin). B. Lung: Papillary adenocarcinoma. (Haematoxylin-eosin). C. Macroscopical changes in liver (box shows the area of the microscopical sections in F–H). D. Macroscopical changes in spleen, control spleen on the left (microscopical sections in I–K). E. Macroscopical changes in paratubarian area (microscopical sections in L–N). F. Cavernous hemangioma featuring focal hyalinization. G. The same tumor mass area with higher magnification (haematoxylin-eosin). H. Weak focal hVEGF-A 165 immunoreactivity was present in the same area (True Blue as a chromogen), arrows indicate positive cells. I–K. Fibrous scars formed by collagenous and elastic fibres surrounded by dilated cystic spaces, focally filled with blood and revealing inconsistently CD34 positive lining. I. Hematoxylin-eosin. (an arrow points to an area shown in K) J. CD34 immunostaining. K. The same area as in I with higher magnification (stained with Masson Trichrom). Asterix in I and J indicate the same area. L. Cystically dilated paratubarian spaces with signs of old haemorrhage and thrombus formation (marked with *), an open circle points to an area which was highly vascularized as shown in M. (CD31 immunostaining) and a box indicates an area which revealed focal hVEGF-A 165 immunopositivity shown in N. (hVEGF-A 165 immunostaining). Bar : F, I, J - 500 µm, G, H, K - 100 µm, A, B, M, N - 200 µm L - 1000 µm.

    Article Snippet: Tissue vascularization was assessed by immunostaining with CD34 antibody (HyCult biotechnology BV, clone MEC 14.7, dilution 1∶20).

    Techniques: Immunostaining, Staining

    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Journal: PLoS ONE

    Article Title: Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2

    doi: 10.1371/journal.pone.0044351

    Figure Lengend Snippet: Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Article Snippet: To visualize endothelial cells within the tumors, sections were incubated with mouse monoclonal anti-CD34 antibody (Hycult Biotech, The Netherlands) during 1 hour at 37°C in a humidity chamber.

    Techniques: Injection, Isolation, Staining, Software